Unlabelled: Sunitinib resistance remains a serious challenge to the treatment of advanced and metastatic renal cell carcinoma (RCC), yet the mechanisms underlying this resistance are not fully understood. Here, we report that the long noncoding RNA IGFL2-AS1 is a driver of therapy resistance in RCC. IGFL2-AS1 was highly upregulated in sunitinib-resistant RCC cells and was associated with poor prognosis in patients with clear cell RCC (ccRCC) who received sunitinib therapy. IGFL2-AS1 enhanced TP53INP2 expression by competitively binding to hnRNPC, a multifunctional RNA-binding protein that posttranscriptionally suppresses TP53INP2 expression through alternative splicing. Upregulated TP53INP2 enhanced autophagy and ultimately led to sunitinib resistance. Meanwhile, IGFL2-AS1 was packaged into extracellular vesicles through hnRNPC, thus transmitting sunitinib resistance to other cells. N6-methyladenosine modification of IGFL2-AS1 was critical for its interaction with hnRNPC. In a patient-derived xenograft model of sunitinib-resistant ccRCC, injection of chitosan-solid lipid nanoparticles containing antisense oligonucleotide-IGFL2-AS1 successfully reversed sunitinib resistance. These findings indicate a novel molecular mechanism of sunitinib resistance in RCC and suggest that IGFL2-AS1 may serve as a prognostic indicator and potential therapeutic target to overcome resistance.
Significance: Extracellular vesicle-packaged IGFL2-AS1 promotes sunitinib resistance by regulating TP53INP2-triggered autophagy, implicating this lncRNA as a potential therapeutic target in renal cell carcinoma.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9811158 | PMC |
| http://dx.doi.org/10.1158/0008-5472.CAN-21-3432 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Patterns of immune evasion in triple-negative breast cancer and new potential therapeutic targets: a review.
Front Immunol
December 2024
Medical Oncology Department, Hospital Arnau de Vilanova, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO), Valencia, Spain.
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer characterized by the absence of progesterone and estrogen receptors and low (or absent) HER2 expression. TNBC accounts for 15-20% of all breast cancers. It is associated with younger age, a higher mutational burden, and an increased risk of recurrence and mortality.
View Article and Find Full Text PDFKinomic profiling to predict sunitinib response of patients with metastasized clear cell Renal Cell Carcinoma.
Neoplasia
December 2024
Radboud University Medical Center, 6525 GA, Nijmegen, the Netherlands.
Introduction: Treatment with Sunitinib, a potent multitargeted receptor tyrosine kinase inhibitor (TKI) has increased the progression-free survival (PFS) and overall-survival (OS) of patients with metastasized renal cell carcinoma (mRCC). With modest OS improvement and variable response and toxicity predictive and/or prognostic biomarkers are needed to personalize patient management: Prediction of individual TKI therapy response and resistance will increase successful treatment outcome while reducing unnecessary drug use and expense. The aim of this study was to investigate whether kinase activity analysis can predict sunitinib response and/or toxicity using tissue samples obtained from primary clear cell RCC (ccRCC) from a cohort of clinically annotated patients with mRCC receiving sunitinib as first-line treatment.
View Article and Find Full Text PDFHigh MICAL-L2 promotes cancer progression and drug resistance in renal clear cell carcinoma cells through stabilization of ACTN4 following vimentin expression.
Biochim Biophys Acta Mol Basis Dis
December 2024
Department of Physiology, Nanjing Medical University, Nanjing, Jiangsu 211166, China. Electronic address:
Targeted therapies persist as the conventional method of treatment of kidney clear cell carcinoma (KIRC). However, resistance to these drugs emerges as a significant impediment to the management of renal cancer. MICAL-L2 plays a pivotal role in cytoskeleton rearrangement.
View Article and Find Full Text PDFIKBKE regulates renal cell carcinoma progression and sunitinib resistance through the RRM2-AKT pathway.
Int J Biol Sci
December 2024
Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Tyrosine kinase inhibitors (TKIs), such as sunitinib, have emerged as promising agents in renal cell carcinoma (RCC) treatment, particularly in patients at advanced/metastatic clinical stages. However, acquired resistance to sunitinib is common following prolonged clinical treatment in RCC. Increasing evidence has demonstrated a strong correlation between inhibitor of nuclear factor kappa B kinase subunit epsilon (IKBKE) and cancer progression as well as drug resistance.
View Article and Find Full Text PDFHsa_circ_0072732 enhances sunitinib resistance of renal cell carcinoma by inhibiting ferroptosis.
Discov Oncol
November 2024
Department of Urology, The First College of Clinical Medical Science, China Three Gorges University, Yichang, 443002, China.
Article Synopsis
- Renal cell carcinoma (RCC) is a common and deadly cancer that shows resistance to sunitinib treatment, making it harder to treat.
- Researchers discovered a specific circular RNA (Hsa_circ_0072732) that is highly expressed in RCC cells and contributes to this resistance by influencing ferroptosis.
- The study indicates that silencing Hsa_circ_0072732 could improve RCC sensitivity to sunitinib, suggesting targeting ferroptosis could be an effective strategy for treatment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!